Farabursen sodium
Based on 1 Customer Validation
Farabursen sodium (RGLS8429 sodium; RG1015 sodium) is a miR-17 inhibitor. Farabursen sodium inhibits the function of the miR-17 family, relieves the inhibitory effect on miR-17 target genes including PKD1 and PKD2, and increases the level of PC1/2. Farabursen sodium slows the growth of renal cysts, reduces the ratio of kidney weight to body weight, and decreases the cyst index and proliferation index. Farabursen sodium is applicable to research related to autosomal dominant polycystic kidney disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 93.56%
- CAS No.: 2921918-19-4
- Formule: C95H107F3N32Na8O50P8S8
- Masse moléculaire:3066.4 (free acid)
-
Stockage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Farabursen (sodium) (0.1-100 nM; 24 h) potently de-represses miR-17 activity in HeLa cells, with an EC50 of 22.40 nM after 24 h of incubation[2].
Farabursen (sodium) (0.1-100 nM; 24 h) de-represses PKD1-3'UTR activity in HeLa cells, with an EC50 of 43.54 nM after 24 h of incubation[2].
Farabursen (sodium) (0.1-100 nM; 24 h) de-represses PKD2-3'UTR activity in HeLa cells, with an EC50 of 40.76 nM after 24 h of incubation[2].
Farabursen (sodium) (120 nM) reduces 3D cyst size in primary human ADPKD cyst cells when transfected at 120 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Farabursen sodium (0-300 mg/kg; s.c.; single dose) achieves sustained target binding to miR-17 in the kidneys of C57BL/6 mice (inhibition rate ≥75%, duration ≥14 days), and also achieves this effect in the liver (inhibition rate ≥75%, duration ≥7 days), with an EC75 of 2.2 μg/g in renal tissues[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (Pkd1F/RC genetic model of ADPKD; treated on postnatal days 8, 10, 12, 15, sacrificed on postnatal day 18)[2]
-
Dosage:20 mg/kg
-
Administration:s.c.; on postnatal days 8, 10, 12, 15
-
Result:Reduced kidney weight-to-body weight (KW/BW) ratio, cyst index, proliferation index, and blood urea nitrogen (BUN) levels compared to PBS control; all reductions were statistically significant.
-
Animal Model:C57BL/6 mice[2]
-
Dosage:03, 0.03, 0.1, 0.3, 1, 3, 10, 30, and 300 mg/kg
-
Administration:s.c.; single dose
-
Result:Achieved kidney target engagement (percent inhibition of miR-17) ≥75% for at least 14 days post-dose.
Achieved liver target engagement ≥75% for at least 7 days post-dose.
Reached an EC75 (kidney concentration required to achieve 75% target engagement) of 2.2 μg/g.
Chemical Information
-
CAS No. 2921918-19-4
-
Appearance Solid
-
Masse moléculaire 3066.4 (free acid)
-
Formule C95H107F3N32Na8O50P8S8
-
Color White to off-white
-
SMILES
[Farabursen (sodium)]
-
Synonyms
RGLS8429 sodium; RG1015 sodium
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Pureté et documentation
-
Fiche technique (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2242 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Farabursen sodium Related Classifications
HY-150364A Related Classifications
Powered by Bioz